• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Corrigendum: Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape.勘误：艾拉莫德作为类风湿关节炎的新药：现状
Front Pharmacol. 2020 Apr 8;11:488. doi: 10.3389/fphar.2020.00488. eCollection 2020.
2
Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape.艾拉莫德作为类风湿关节炎的新药：现状
Front Pharmacol. 2020 Feb 26;11:73. doi: 10.3389/fphar.2020.00073. eCollection 2020.
3
Corrigendum: A Chinese medicine formula (kunbixiao granule) for female rheumatoid arthritis: Study protocol for a double-blind, randomized, placebo-controlled trial.勘误：一种用于女性类风湿性关节炎的中药配方（昆痹消颗粒）：一项双盲、随机、安慰剂对照试验的研究方案。
Front Pharmacol. 2022 Nov 3;13:1074679. doi: 10.3389/fphar.2022.1074679. eCollection 2022.
4
Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial.艾拉莫德与甲氨蝶呤联合治疗对甲氨蝶呤反应不足的活动性类风湿关节炎患者的安全性和有效性：一项随机、双盲、安慰剂对照试验的开放标签扩展研究
Mod Rheumatol. 2014 May;24(3):410-8. doi: 10.3109/14397595.2013.843756. Epub 2013 Nov 7.
5
A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide.一种新型的疾病修饰抗风湿药物，依古替莫德，通过阻断白介素-17 信号通路来改善关节炎，与甲氨蝶呤和来氟米特不同。
J Immunol. 2013 Nov 15;191(10):4969-78. doi: 10.4049/jimmunol.1300832. Epub 2013 Oct 11.
6
Corrigendum: An integrative pharmacology model for decoding the underlying Therapeutic Mechanisms of Ermiao Powder for Rheumatoid arthritis.勘误：一种用于解读二妙散治疗类风湿关节炎潜在治疗机制的整合药理学模型。
Front Pharmacol. 2023 Oct 9;14:1302388. doi: 10.3389/fphar.2023.1302388. eCollection 2023.
7
Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial.在甲氨蝶呤稳定剂量治疗下仍处于活动期的类风湿关节炎患者中联合使用来氟米特治疗：一项随机、双盲、安慰剂对照试验。
Mod Rheumatol. 2013 May;23(3):430-9. doi: 10.1007/s10165-012-0724-8. Epub 2012 Jul 26.
8
Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-κB and MAPK pathways.艾拉莫德（T-614）通过NF-κB和MAPK信号通路抑制RANKL诱导的RAW264.7细胞破骨细胞分化和迁移。
Int Immunopharmacol. 2016 Jun;35:294-300. doi: 10.1016/j.intimp.2016.03.038. Epub 2016 Apr 16.
9
Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study.艾拉莫德与安慰剂及柳氮磺胺吡啶治疗活动性类风湿关节炎的疗效和安全性比较：一项对照、多中心、双盲、平行组研究
Mod Rheumatol. 2007;17(1):1-9. doi: 10.1007/s10165-006-0542-y. Epub 2007 Feb 20.
10
Regulatory Effect of Iguratimod on the Balance of Th Subsets and Inhibition of Inflammatory Cytokines in Patients with Rheumatoid Arthritis.艾拉莫德对类风湿关节炎患者Th亚群平衡及炎性细胞因子的调控作用
Mediators Inflamm. 2015;2015:356040. doi: 10.1155/2015/356040. Epub 2015 Dec 2.

引用本文的文献

1
Signaling pathways in rheumatoid arthritis: implications for targeted therapy.类风湿关节炎中的信号通路：靶向治疗的意义。
Signal Transduct Target Ther. 2023 Feb 17;8(1):68. doi: 10.1038/s41392-023-01331-9.

本文引用的文献

1
The three-year efficacy of iguratimod in clinical daily practice in patients with rheumatoid arthritis.来氟米特治疗类风湿关节炎的三年疗效观察。
Mod Rheumatol. 2019 Sep;29(5):775-781. doi: 10.1080/14397595.2018.1510879. Epub 2018 Dec 20.
2
The add-on effectiveness and safety of iguratimod in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab.对于托珠单抗治疗反应不足的类风湿关节炎患者，艾拉莫德的附加疗效及安全性。
Mod Rheumatol. 2019 Jul;29(4):581-588. doi: 10.1080/14397595.2018.1486939. Epub 2018 Jul 23.
3
Iguratimod is effective in refractory rheumatoid arthritis patients with inadequate response to methotrexate-cyclosporin A-hydroxychloroquine-prednisone.艾拉莫德对甲氨蝶呤-环孢素A-羟氯喹-泼尼松治疗反应不佳的难治性类风湿关节炎患者有效。
Scand J Rheumatol. 2018 Sep;47(5):422-424. doi: 10.1080/03009742.2017.1376109. Epub 2018 Jan 10.
4
Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study.对于对生物性改善病情抗风湿药反应不佳的类风湿关节炎患者，加用艾拉莫德作为实现缓解的治疗策略：一项回顾性研究。
Mod Rheumatol. 2018 Mar;28(2):227-234. doi: 10.1080/14397595.2017.1336865. Epub 2017 Jun 23.
5
Iguratimod in combination with methotrexate in active rheumatoid arthritis : Therapeutic effects.艾拉莫德联合甲氨蝶呤治疗活动性类风湿关节炎：疗效观察
Z Rheumatol. 2016 Oct;75(8):828-833. doi: 10.1007/s00393-015-1641-y.
6
Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial.艾拉莫德与甲氨蝶呤联合治疗对活动期类风湿关节炎患者的疗效和安全性评估：一项随机对照试验
Clin Rheumatol. 2015 Sep;34(9):1513-9. doi: 10.1007/s10067-015-2999-6. Epub 2015 Jul 4.
7
Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial.艾拉莫德与甲氨蝶呤联合治疗对甲氨蝶呤反应不足的活动性类风湿关节炎患者的安全性和有效性：一项随机、双盲、安慰剂对照试验的开放标签扩展研究
Mod Rheumatol. 2014 May;24(3):410-8. doi: 10.3109/14397595.2013.843756. Epub 2013 Nov 7.
8
Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial.在甲氨蝶呤稳定剂量治疗下仍处于活动期的类风湿关节炎患者中联合使用来氟米特治疗：一项随机、双盲、安慰剂对照试验。
Mod Rheumatol. 2013 May;23(3):430-9. doi: 10.1007/s10165-012-0724-8. Epub 2012 Jul 26.

勘误：艾拉莫德作为类风湿关节炎的新药：现状

Corrigendum: Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape.

作者信息

Xie Sisi, Li Shu, Tian Jing, Li Fen

机构信息

Department of Internal Medicine, The 2nd Xiangya Hospital of Central South University, Changsha, China.

出版信息

Front Pharmacol. 2020 Apr 8;11:488. doi: 10.3389/fphar.2020.00488. eCollection 2020.

DOI:10.3389/fphar.2020.00488
PMID:32372962
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7179687/
Abstract

[This corrects the article DOI: 10.3389/fphar.2020.00073.].

摘要

[本文更正了文章DOI：10.3389/fphar.2020.00073。]